On 22 February 2017 , TalkMed had announced a bonus issue of new ordinary shares in the share capital of the Company (the “Bonus Shares”) to the shareholders of the Company on the basis of one Bonus Share for every one existing ordinary share .
It is definitely a good news to me as the price have surged up by more than 30% based on my entry price.
I might dispose some of my TalkMed shares after cum bonus which I will blog about it in the future.
The balance sheet is still strong with little debts. Operating Expenses have go up in tandem with expanded operations.
Overall , not much changes as compared to FY 2015 except for the mounting losses from its associate Hong Kong Integrated Oncology Centre Holdings Limited at $3.63 million for FY 2016.
Revenue
Revenue for FY 2016 was $68.91 million, an increase of $3.19 million or 4.9% from $65.72 million FY 2015
Revenue derived from operations in Vietnam, TalkMed Vietnam Pte. Ltd , which is 60%-owned subsidiary, during the year amounted to $0.40 million. This was an increase of $0.07 million or 21.3% over last year.
Revenue derived from Stem Med Pte.which is 40%-owned subsidiary, for stem cell processing and storage services during the year amounted to $0.40 million. This was an increase of $0.30 million or 300.0% over last year as Stem Med commenced its operations in July 2015.
Profit
Profit after tax at $36.88 million , a 0.8% decrease of $37.17 million compared to FY2015 .
Expense
Other operating expense increase by 54.5% at $2.34 million as compared to FY2015 $1.51 million due to overhead expenses incurred by Stem Med which commenced operations in July 2015
Result of Associate
Hong Kong Integrated Oncology Centre Holdings Limited was $0.84 million and $3.63 million in Q4 2016 and FY 2016 respectively. The loss was mainly due to higher operating expenses as HKH is in its gestation period.
It is definitely a good news to me as the price have surged up by more than 30% based on my entry price.
I might dispose some of my TalkMed shares after cum bonus which I will blog about it in the future.
The balance sheet is still strong with little debts. Operating Expenses have go up in tandem with expanded operations.
Overall , not much changes as compared to FY 2015 except for the mounting losses from its associate Hong Kong Integrated Oncology Centre Holdings Limited at $3.63 million for FY 2016.
Revenue
Revenue for FY 2016 was $68.91 million, an increase of $3.19 million or 4.9% from $65.72 million FY 2015
Revenue derived from operations in Vietnam, TalkMed Vietnam Pte. Ltd , which is 60%-owned subsidiary, during the year amounted to $0.40 million. This was an increase of $0.07 million or 21.3% over last year.
Revenue derived from Stem Med Pte.which is 40%-owned subsidiary, for stem cell processing and storage services during the year amounted to $0.40 million. This was an increase of $0.30 million or 300.0% over last year as Stem Med commenced its operations in July 2015.
Profit
Profit before tax remains unchanged at $45.48 million as compared to FY2015.
Expense
Other operating expense increase by 54.5% at $2.34 million as compared to FY2015 $1.51 million due to overhead expenses incurred by Stem Med which commenced operations in July 2015
Result of Associate
Hong Kong Integrated Oncology Centre Holdings Limited was $0.84 million and $3.63 million in Q4 2016 and FY 2016 respectively. The loss was mainly due to higher operating expenses as HKH is in its gestation period.
Comments
Post a Comment